NYSE:WST West Pharmaceutical Services (WST) Stock Price, News & Analysis $413.46 +2.16 (+0.52%) As of 11:50 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About West Pharmaceutical Services Stock (NYSE:WST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get WST alerts:Sign Up Key Stats Today's Range$409.00▼$414.3050-Day Range$337.66▼$416.5552-Week Range$223.83▼$438.27Volume61,054 shsAverage Volume803,476 shsMarket Capitalization$28.80 billionP/E Ratio46.39Dividend Yield0.25%Price Target$424.67Consensus RatingModerate Buy Company Overview West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines. Founded in 1923 by Herman O. West, the company is headquartered in Exton, Pennsylvania, and serves customers around the world through its global operations.AI Generated. May Contain Errors. Read More West Pharmaceutical Services Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreWST MarketRank™: 3.92800944138 of 5 starsWest Pharmaceutical Services scored higher than 79% of companies evaluated by MarketBeat, and ranked 106th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingModerate Buy Consensus RatingWest Pharmaceutical Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for West Pharmaceutical Services is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageWest Pharmaceutical Services has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about West Pharmaceutical Services' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.35% Earnings GrowthEarnings for West Pharmaceutical Services are expected to grow by 8.35% in the coming year, from $9.46 to $10.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of West Pharmaceutical Services is 46.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.72.Price to Earnings Ratio vs. SectorThe P/E ratio of West Pharmaceutical Services is 46.17, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.41.Price to Earnings Growth RatioWest Pharmaceutical Services has a PEG Ratio of 2.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioWest Pharmaceutical Services has a P/B Ratio of 9.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.61% of the float of West Pharmaceutical Services has been sold short.Short Interest Ratio / Days to CoverWest Pharmaceutical Services has a short interest ratio ("days to cover") of 2.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in West Pharmaceutical Services has recently decreased by 10.24%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldWest Pharmaceutical Services has a dividend yield of 0.25%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthWest Pharmaceutical Services does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of West Pharmaceutical Services is 11.67%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 10.15% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.Read more about West Pharmaceutical Services' dividend. News and Social Media4.0 / 5News Sentiment1.47 News SentimentWest Pharmaceutical Services has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for West Pharmaceutical Services this week, compared to 6 articles on an average week.Search Interest12 people have searched for WST on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows6 people have added West Pharmaceutical Services to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, West Pharmaceutical Services insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,443,749.00 in company stock.Percentage Held by Insiders0.60% of the stock of West Pharmaceutical Services is held by insiders.Percentage Held by Institutions93.90% of the stock of West Pharmaceutical Services is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about West Pharmaceutical Services' insider trading history. Receive WST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WST Stock News HeadlinesWest Pharmaceutical Services (WST) Stock May Be 29% Overvalued On Cash Flow Views2 hours ago | finance.yahoo.comAnalyzing Medline (NASDAQ:MDLN) and West Pharmaceutical Services (NYSE:WST)November 10 at 2:29 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)West to Participate in Upcoming Investor ConferenceNovember 4, 2026 | prnewswire.comWest Pharmaceutical Services consensus price target raised 12.52% to $467.89November 3, 2026 | msn.comWest Pharmaceutical Services Raises Outlook After Strong Earnings CallNovember 2, 2026 | tipranks.comWest Pharmaceutical Services, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 2, 2026 | seekingalpha.comWest Pharmaceutical Services (NYSE:WST) Price Target Raised to $494.00November 2, 2026 | americanbankingnews.comSee More Headlines WST Stock Analysis - Frequently Asked Questions How have WST shares performed this year? West Pharmaceutical Services' stock was trading at $275.53 on January 1st, 2026. Since then, WST shares have increased by 49.3% and is now trading at $411.4890. How were West Pharmaceutical Services' earnings last quarter? West Pharmaceutical Services, Inc. (NYSE:WST) posted its quarterly earnings results on Thursday, October, 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.20 by $0.46. The company's revenue for the quarter was up 8.7% compared to the same quarter last year. Read the conference call transcript. How will West Pharmaceutical Services' stock buyback program work? West Pharmaceutical Services' Board of Directors initiated a share buyback program on Tuesday, February 17th 2026, which permits the company to buy back $1 billion in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5.6% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its stock is undervalued. Does West Pharmaceutical Services have any subsidiaries? West Pharmaceutical Services subsidiaries include these companies: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., The Tech Group Inc., Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), TGPR Holdings Limited, WD SG Pte. Ltd., and others. Who are West Pharmaceutical Services' major shareholders? Top institutional investors of West Pharmaceutical Services include State Street Corp (4.78%), Aberdeen Group plc (2.10%), ProShare Advisors LLC (0.67%) and William Blair Investment Management LLC (0.57%). Insiders that own company stock include Eric Mark Green, Thomas W Hofmann, Annette F Favorite, Silji Abraham, Chad Winters and Charles Witherspoon. View institutional ownership trends. How do I buy shares of West Pharmaceutical Services? Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of West Pharmaceutical Services own? Based on aggregate information from My MarketBeat watchlists, some other companies that West Pharmaceutical Services investors own include NVIDIA (NVDA), PayPal (PYPL), AbbVie (ABBV), Tesla (TSLA), Walmart (WMT), Johnson & Johnson (JNJ) and Home Depot (HD). Company Calendar Last Earnings10/29/2026Ex-Dividend for 11/18 Dividend11/10/2026Record date for 11/18 Dividend11/11/2026Today11/13/2026Dividend Payable11/18/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 WST's financial health is in the Green zone, according to TradeSmith. WST has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Supplies Current SymbolNYSE:WST CIK105770 Webwww.westpharma.com Phone(610) 594-2900Fax800-345-9800Employees10,800Year Founded1923Price Target and Rating Average Price Target for West Pharmaceutical Services$424.67 High Price Target$500.00 Low Price Target$315.00 Potential Upside/Downside+2.6%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$8.91 Trailing P/E Ratio46.47 Forward P/E Ratio40.40 P/E Growth2.51Net Income$493.70 million Net Margins18.81% Pretax Margin23.24% Return on Equity21.78% Return on Assets15.99% Debt Debt-to-Equity Ratio0.07 Current Ratio2.82 Quick Ratio2.10 Sales & Book Value Annual Sales$3.07 billion Price / Sales9.38 Cash Flow$9.77 per share Price / Cash Flow42.40 Book Value$42.61 per share Price / Book9.72Miscellaneous Outstanding Shares69,660,000Free Float69,243,000Market Cap$28.84 billion OptionableOptionable Beta1.13 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:WST) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding West Pharmaceutical Services, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share West Pharmaceutical Services With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
